CR8350A - 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogenica cronica - Google Patents

4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogenica cronica

Info

Publication number
CR8350A
CR8350A CR8350A CR8350A CR8350A CR 8350 A CR8350 A CR 8350A CR 8350 A CR8350 A CR 8350A CR 8350 A CR8350 A CR 8350A CR 8350 A CR8350 A CR 8350A
Authority
CR
Costa Rica
Prior art keywords
quinolincarbonitrilos
anilino
treatment
myelogenic leukemia
chronic myelogenic
Prior art date
Application number
CR8350A
Other languages
English (en)
Spanish (es)
Inventor
Charles Boschelli Frank
Michele Golas Jennifer
Tomothy Arndt Kim
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8350(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8350A publication Critical patent/CR8350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CR8350A 2003-11-06 2006-04-20 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogenica cronica CR8350A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51781903P 2003-11-06 2003-11-06

Publications (1)

Publication Number Publication Date
CR8350A true CR8350A (es) 2006-10-06

Family

ID=34590192

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8350A CR8350A (es) 2003-11-06 2006-04-20 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogenica cronica

Country Status (18)

Country Link
US (2) US7417148B2 (enExample)
EP (1) EP1680119A1 (enExample)
JP (1) JP2007533655A (enExample)
KR (1) KR20060118461A (enExample)
CN (1) CN1874776A (enExample)
AU (1) AU2004289243B2 (enExample)
BR (1) BRPI0416289A (enExample)
CA (1) CA2543163A1 (enExample)
CO (1) CO5690608A2 (enExample)
CR (1) CR8350A (enExample)
EC (1) ECSP066548A (enExample)
IL (1) IL175424A0 (enExample)
MX (1) MXPA06004744A (enExample)
NO (1) NO20062255L (enExample)
RU (1) RU2006113691A (enExample)
SG (1) SG146681A1 (enExample)
WO (1) WO2005046693A1 (enExample)
ZA (1) ZA200603596B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004289243B2 (en) * 2003-11-06 2010-07-22 Wyeth Llc 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
JP5121706B2 (ja) * 2005-06-17 2013-01-16 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Ｓｒｃキナーゼ阻害薬による溶骨性病変の阻害
BRPI0611977A2 (pt) * 2005-06-24 2010-10-13 Wyeth Corp uso de um composto
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
CA2868899C (en) * 2007-06-01 2017-06-13 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
US9776970B2 (en) 2014-02-20 2017-10-03 Apotex Inc. Bosutinib forms and preparation methods thereof
SG11201705767PA (en) 2015-01-13 2017-08-30 Univ Kyoto Agent for preventing and/or treating amyotrophic lateral sclerosis
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US12398355B2 (en) 2019-04-09 2025-08-26 Massachusetts Institute Of Technology Micro physiological model for neuronal and muscular diseases and disorders
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20040229880A1 (en) 2003-02-21 2004-11-18 Wyeth 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
AU2004289243B2 (en) * 2003-11-06 2010-07-22 Wyeth Llc 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)

Also Published As

Publication number Publication date
US20100029677A1 (en) 2010-02-04
ZA200603596B (en) 2009-12-30
AU2004289243B2 (en) 2010-07-22
NO20062255L (no) 2006-08-01
MXPA06004744A (es) 2006-07-05
RU2006113691A (ru) 2007-12-20
US20050101780A1 (en) 2005-05-12
WO2005046693A1 (en) 2005-05-26
ECSP066548A (es) 2006-10-17
AU2004289243A1 (en) 2005-05-26
CN1874776A (zh) 2006-12-06
JP2007533655A (ja) 2007-11-22
CO5690608A2 (es) 2006-10-31
IL175424A0 (en) 2008-04-13
CA2543163A1 (en) 2005-05-26
SG146681A1 (en) 2008-10-30
KR20060118461A (ko) 2006-11-23
BRPI0416289A (pt) 2007-01-23
EP1680119A1 (en) 2006-07-19
US7417148B2 (en) 2008-08-26
US7919625B2 (en) 2011-04-05

Similar Documents

Publication Publication Date Title
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
TW200637853A (en) Fungicides
EA201000395A1 (ru) Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида
UY28290A1 (es) Compuestos farmacéuticos novedosos
SV2005001973A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
CL2007002390A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de leucemia y discrasias hematologicas.
CY1110064T1 (el) Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
ECSP088369A (es) Novedosos derivados de 1-aza-bicicloalquilo para el tratamiento de trastornos psicóticos y neurodegenerativos
CR8644A (es) Compuestos de imidazol para el tratamiento de transtornos neurodegenerativos
EA201000396A1 (ru) Новые фунгициды
GT200300087A (es) 2-(2,6-diclorofenil)-diarilimidazoles
TW200637837A (en) Fungicides
ECSP077360A (es) Compuestos sulfonamida
EA201000269A1 (ru) Новые гербициды
CR8350A (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogenica cronica
DE60319349D1 (de) Spiroverbindungen mit npy antagonistischer wirkung
ATE483000T1 (de) Naphtalin-amidin-imide
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
CR10637A (es) Fungicidas
SE0103710D0 (sv) Compounds
CY1108226T1 (el) Αντικαρκινικες ενωσεις βασισμενες σε καχαλαλιδης f
ECSP077130A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de náuseas y vómitos
ATE516291T1 (de) Thenopyrimidin-verbindungen mit fungizider aktivität

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)